RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF FREMANEZUMAB IN PATIENTS (6 TO 17 YEARS) WITH EPISODIC MIGRAINE

Registry ID

TV48125-CNS-30083

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D INC

Start date

2021-01-29

Last update

2020-11-10

Conditions

• EPISODIC MIGRAINE

Related clinical trials

• A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ESCALATION AND DOSE FINDING PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPN10200 IN THE PREVENTION OF EPISODIC OR CHRONIC MIGRAINE IN ADULTS (MERANTI)
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL WITH EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF XEOMIN® INJECTIONS FOR THE PREVENTION OF EPISODIC MIGRAINE
• A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PARALLEL-GROUP STUDY WITH EXTENSION PHASE TO EVALUATE THE EFFICACY AND SAFETY OF DYSPORT® FOR THE PREVENTION OF EPISODIC MIGRAINE IN ADULT PARTICIPANTS
• INTERVENTIONAL, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS (IV) EPTINEZUMAB IN PAEDIATRIC PATIENTS (6 TO 17 YEARS) FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE
• A PHASE 3, MULTICENTER, 12-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ATOGEPANT FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN PEDIATRIC SUBJECTS 6 TO 17 YEARS OF AGE
• LONG TERM, OPEN LABEL (DOSE BLINDED), EXTENSION STUDY OF EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH CHRONIC OR EPISODIC MIGRAINE

View on source registry